294 related articles for article (PubMed ID: 21175376)
1. Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system.
Michallet M; Gangneux JP; Lafuma A; Herbrecht R; Ribaud P; Caillot D; Dupont B; Moreau P; Berger P; O'Sullivan AK
J Med Econ; 2011; 14(1):28-35. PubMed ID: 21175376
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
Stam WB; O'Sullivan AK; Rijnders B; Lugtenburg E; Span LF; Janssen JJ; Jansen JP
Eur J Haematol; 2008 Dec; 81(6):467-74. PubMed ID: 18754857
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.
Al-Badriyeh D; Slavin M; Liew D; Thursky K; Downey M; Grigg A; Bajel A; Stewart K; Kong DC
J Antimicrob Chemother; 2010 May; 65(5):1052-61. PubMed ID: 20237074
[TBL] [Abstract][Full Text] [Related]
4. Adapting a global cost-effectiveness model to local country requirements: posaconazole case study.
Papadopoulos G; Hunt S; Prasad M
J Med Econ; 2013; 16(3):374-80. PubMed ID: 23256900
[TBL] [Abstract][Full Text] [Related]
5. [Cost effectiveness of posaconazole versus fluconazole/itraconazole in the prophylactic treatment of invasive fungal infections in Mexico].
Rely K; Alexandre PK; Escudero GS
Value Health; 2011; 14(5 Suppl 1):S39-42. PubMed ID: 21839897
[TBL] [Abstract][Full Text] [Related]
6. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT.
de la Cámara R; Jarque I; Sanz MA; Grau S; Casado MA; Sabater FJ; Carreras E
Bone Marrow Transplant; 2010 May; 45(5):925-32. PubMed ID: 19802030
[TBL] [Abstract][Full Text] [Related]
8. Posaconazole vs fluconazole/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: a cost-effectiveness analysis in Greece.
Athanasakis K; Petrakis I; Kyriopoulos J
J Med Econ; 2013; 16(5):678-84. PubMed ID: 23448409
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in Switzerland.
Greiner RA; Meier Y; Papadopoulos G; O'Sullivan AK; Imhof A
Oncology; 2010; 78(3-4):172-80. PubMed ID: 20414005
[TBL] [Abstract][Full Text] [Related]
10. An update to the cost-effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States.
Sung AH; Marcella SW; Xie Y
J Med Econ; 2015 May; 18(5):341-8. PubMed ID: 25524741
[TBL] [Abstract][Full Text] [Related]
11. SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy.
Busca A; Lessi F; Verga L; Candoni A; Cattaneo C; Cesaro S; Dragonetti G; Delia M; De Luca A; Guglielmi G; Tumbarello M; Martino G; Nadali G; Fanci R; Picardi M; Potenza L; Nosari A; Aversa F; Pagano L;
Leuk Lymphoma; 2017 Dec; 58(12):2859-2864. PubMed ID: 28508692
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
[TBL] [Abstract][Full Text] [Related]
13. Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis.
Heimann SM; Cornely OA; Vehreschild MJ; Glossmann J; Kochanek M; Kreuzer KA; Hallek M; Vehreschild JJ
Mycoses; 2014 Feb; 57(2):90-7. PubMed ID: 23790060
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden.
Lundberg J; Höglund M; Björkholm M; Åkerborg Ö
Clin Drug Investig; 2014 Jul; 34(7):483-9. PubMed ID: 24820968
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with posaconazole prophylaxis--a retrospective analysis in a haematological unit.
Hahn J; Stifel F; Reichle A; Holler E; Andreesen R
Mycoses; 2011 Jan; 54 Suppl 1():12-6. PubMed ID: 21126267
[TBL] [Abstract][Full Text] [Related]
16. [Economic evaluation of posaconazole in prophylaxis of invasive fungal infections in Italian neutropenic patients with acute myeloid leukaemia or myelodysplastic syndrome].
Lazzaro C
Infez Med; 2010 Jun; 18(2):91-103. PubMed ID: 20610931
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation.
Sánchez-Ortega I; Patiño B; Muñoz C; Arnan M; Peralta T; Clopés A; de Sevilla AF; Duarte RF
J Med Econ; 2013; 16(6):736-43. PubMed ID: 23541251
[TBL] [Abstract][Full Text] [Related]
18. Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study.
Shen Y; Huang XJ; Wang JX; Jin J; Hu JD; Yu K; Wu DP; Wang SJ; Yu L; Chen XQ; Liu T; Liang YM; Chen FP; Li Y; Shen ZX
Int J Clin Pharmacol Ther; 2013 Sep; 51(9):738-45. PubMed ID: 23924680
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States.
O'Sullivan AK; Pandya A; Papadopoulos G; Thompson D; Langston A; Perfect J; Weinstein MC
Value Health; 2009; 12(5):666-73. PubMed ID: 19508661
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of anti-fungal but not anti-bacterial prophylaxis in intensive primary AML therapy: a real-world, retrospective comparative single-centre study.
Gerber B; Köppel J; Paul M; Nguyen-Kim TD; Frauenfelder T; Nair G; Schanz U; Manz MG
Swiss Med Wkly; 2014; 144():w13985. PubMed ID: 25055166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
